E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Luteal phase support in patients undergoing Assisted Reproductive Technology (IVF). |
Supporto della fase luteale in pazienti sottoposte a trattamenti di procreazione medicalmente assistita (IVF. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021926 |
E.1.2 | Term | Infertility |
E.1.2 | System Organ Class | 10038604 - Reproductive system and breast disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of a new progesterone formulation to be used for luteal support in IVF (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg, versus Crinone administered intravaginally at 90 mg daily. |
valutare l'efficacia della nuova formulazione di Progesterone (IBSA) somministrata tramite iniezione sottocutanea ad un dosaggio giornaliero di 25 mg, in confronto al Crinone somministrato per via vaginale al dosaggio di 90 mg al giorno nel supporto della fase luteale in pazienti sottoposte a cicli IVF. |
|
E.2.2 | Secondary objectives of the trial |
to evaluate the tolerability of the product |
valutare la tollerabilita' del prodotto |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18- 42 (upon starting COH); - BMI <30 kg/m2; - <3 prior ART cycles (IVF, ICSI and related procedures); - Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL; - Normal uterine cavity as per recent hysterosalpingogram, sonohystogram or hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid); - At least 3 retrieved oocytes; - Patient has given written informed consent. |
- Eta` compresa tra 18 42 anni (al momento dell inizio della stimolazione); - BMI <30 kg/m2; - <3 cicli ART precedenti allo studio (IVF, ICSI e procedure simili); - Livelli basali (al giorno 2-3 del ciclo) di FSH ≤15 IU/L e di E2 <80 pg/mL; - Cavita` uterine normale dimostrata tramite isterosalpingografia, sonoisterografia o esame isteroscopico (i.e. assenza di polipi o fibroma sotto-mucoso sporgente); - Recupero di almeno 3 ovociti; - La paziente ha firmato il formulario di consenso informato. |
|
E.4 | Principal exclusion criteria |
Intramural uterine fibroids that distort the uterine cavity or polyps > 1 cm; Stage III or IV endometriosis (endometriomas); Hydrosalpinx; History of past poor response to COH resulting in cancelling ART; Use of thawed/donated oocytes; Use of thawed/donated embryos; Patients affected by pathologies associated with any contraindication of being pregnant; Hypersensitivity to study medication; Uncontrolled adrenal or thyroid dysfunction; Undiagnosed vaginal bleeding; History of arterial disease; Patients with hepatic impairment; Neoplasias (current) or history of neoplasia that may be responsive to progesterone; High grade cervical dysplasia; History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages wherein pregnancy developed to a minimum of a gestational sac on TVUS; Participation in a concurrent clinical trial or another trial within the past 2 months; Use of concomitant medications that might interfere with the study evaluation; Pre-implantation genetic diagnosis/screening. - Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders; |
- Presenza di un fibroma intramurale uterino deformante la cavita` uterina o presenza di polipi >1 cm; - Endometriosi di stadio III o IV (presenza di endometriomi); - Idrosalpinge; - Precedenti esperienze di cancellazione del ciclo di stimolazione a causa di una debole risposta al trattamento; - Utilizzo di ovociti scongelati o donati; - Utilizzo di embrioni scongelati o donati; - Presenza di patologie controindicanti una gravidanza - Ipersensitivita` al farmaco in studio; - Disfunzione surrenale o tiroidea non controllata; - Sanguinamento vaginale anormale o di origine indeterminata; - Patologie arteriose pregresse; - Severa menomazione delle funzioni epatiche; - Neoplasia attuale o pregressa potenzialmente ricettiva al progesterone; - Grave displasia cervicale; - Soggetto ad aborto abituale ripetuto definito come interruzione spontanea di 3 o piu` gravidanze con presenza di sacco gestazionale dimostrata ecograficamente; - Attuale partecipazione in uno studio clinico o partecipazione in un altro studio clinico negli ultimi 2 mesi; - Utilizzo di medicamenti concomitanti che potrebbero interferire con la valutazione dello studio; - Diagnosi/screening genetico pre-impianto; - Tromboflebite attiva o problemi tromboembolici, o storia di pregresse tromboflebiti o pregressi fenomeni tromboembolici ormone- associati; |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Ongoing pregnancy rate at the end of the study (10 weeks of luteal support). |
- Percentuale di gravidanze evolutive alla fine dello studio (alla 10a settimana di supporto luteale). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
conclusione: ultima visita ultimo soggetto. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 0 |